<DOC>
	<DOCNO>NCT01813448</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ( PK ) single multiple ascend dos fidaxomicin healthy subject . This study also compare safety , tolerability PK single multiple dos fidaxomicin healthy Japanese Caucasian subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics Single Multiple Ascending Doses Fidaxomicin Healthy Male Japanese Caucasian Subjects</brief_title>
	<detailed_description>Eligible subject check unit Day-2 remain confine clinical unit Day 17 . Cohorts 2 3 , may run parallel , enrol review available safety data Cohort 1 Safety Review Team .</detailed_description>
	<criteria>1 . Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout study period 90 day final study drug administration 2 . Male subject must donate sperm start Screening throughout study period least 90 day final study drug administration Inclusion Criteria Japanese Subjects 3 . The subject healthy Japanese male maintain Japanese lifestyle , include diet body mass index ( BMI ) 18.0 28.0 kg/m2 , inclusive . Inclusion Criteria Caucasian Subjects 4 . The subject healthy Caucasian male BMI 18.0 32.0 kg/m2 , inclusive 1 . The subject clinically significant disease history 2 . The subject history current C.difficile infection history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( history appendectomy , hernia repair , and/or cholecystectomy permit ) 3 . The subject clinically significant abnormality 4 . The subject resting ( i.e. , seat 5 minute ) pulse &lt; 40 &gt; 90 beat per minute ( bpm ) Screening Day 2 5 . The subject hypertension ( define seat systolic blood pressure [ SBP ] &gt; 140 mmHg seat diastolic blood pressure [ DBP ] &gt; 90 mmHg ) hypotension ( define seat SBP &lt; 90 mmHg seat DBP &lt; 50 mmHg ) Screening Day 2 6 . The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic checkin Day 2 7 . The subject history chronic diarrhea constipation 8 . The subject positive result hepatitis C antibodies hepatitis B surface antigen Screening know positive history human immunodeficiency virus ( HIV ) 9 . The subject know suspect allergy hypersensitivity component fidaxomicin , macrolide antibacterial class compound , history multiple and/or severe allergy drug food history severe anaphylactic reaction</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Fidaxomicin</keyword>
	<keyword>OPT-80</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>